Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment.
about
Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Tumour vasculature immaturity, ...... ents on bevacizumab treatment.
@en
Tumour vasculature immaturity, ...... ents on bevacizumab treatment.
@nl
type
label
Tumour vasculature immaturity, ...... ents on bevacizumab treatment.
@en
Tumour vasculature immaturity, ...... ents on bevacizumab treatment.
@nl
prefLabel
Tumour vasculature immaturity, ...... ents on bevacizumab treatment.
@en
Tumour vasculature immaturity, ...... ents on bevacizumab treatment.
@nl
P2093
P2860
P50
P356
P1433
P1476
Tumour vasculature immaturity, ...... ents on bevacizumab treatment.
@en
P2093
Aoife Maguire
Blathnaid Nolan
David Fennelly
Diarmuid O'Donoghue
Hugh Mulcahy
John Hyland
Kieran Sheahan
Miriam Tosetto
Petra Martin
Shane Ó'Meachair
P2860
P304
10536-10548
P356
10.18632/ONCOTARGET.24276
P407
P577
2018-01-19T00:00:00Z